Overweight and obesity. Simple obesity NOS
Conditions
Interventions
Intervention 1: Intervention group:
In the intervention group 1000 mg pomegranate extract through two capsules one of each had 500 mg was consumed daily for 30 days. Intervention 2: Control group:
I
Placebo
Intervention group:
In the intervention group 1000 mg pomegranate extract through two capsules one of each had 500 mg was consumed daily for 30 days.
Control group:
In the control group, 1000 mg identical placebo made by pure crystalline was consumed daily through two capsules one of each had 500 mg placebo for 30 days.
Sponsors
Vice Chancellor for research of Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Willingness to participation; Between the age 30-60 years old and Having a BMI within the range 25-40 kgm2; does not have a history of use of any dietary supplements within 3 months prior to the study; does not smoking or alcohol consumption; does not take any cholesterol; triglyceride as well as blood lowering medicine; does not suffer from any acute condition which needs treatment; does not suffer from metabolic stress, infection or inflammation; does not suffer from abnormal liver or kidney function; without any history of heart disease; does not take estrogen and progesterone; does not suffer from poly cyctic ovarian syndrome; not be pregnant or does not lactating. Exclusion criteria:; meet any aforementioned condition which can exclude the participants from the study ; present any changes in the diet or physical activity.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IL-6. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany).;MDA. Timepoint: 30 days. Method of measurement: IL-6 was measured by ELISA kits (BioCore, Germany). | — |
Secondary
| Measure | Time frame |
|---|---|
| Hs-CRP. Timepoint: 30 days. Method of measurement: ELISA method using using commercial ELISA kit (Biochem, Ontario, Canada).;Glucose. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;Cholestrol. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;HDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;LDL-C. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran).;Insulin. Timepoint: 30 days. Method of measurement: determined through an enzymatic calorimetric method using glucose oxidase by commercial kits (Pars azmoon, Tehran, Iran). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ahmad Saedi
Tehran University of Medical Sciences
Outcome results
None listed